About Biva 250 mg/5 ml IV Injection
Made by Healthcare Pharmaceuticals Ltd., Biva is a iv injection whose active ingredient is Bivalirudin. Bivalirudin is indicated for: Anticoagulant in Patients Undergoing PTCA/PCI or PCI with HITS/HITTS Unstable Angina/Non-ST-Elevation MI (Off-label) STEMI Undergoing Primary PCI (Off-label) Heparin-induced Thrombocytopenia Ask your doctor whether it is right for your condition.
What is Biva 250 mg/5 ml IV Injection?
Biva 250 mg/5 ml iv injection is a medicine made by Healthcare Pharmaceuticals Ltd. Bivalirudin is indicated for: Anticoagulant in Patients Undergoing PTCA/PCI or PCI with HITS/HITTS Unstable Angina/Non-ST-Elevation MI (Off-label) STEMI Undergoing Primary PCI (Off-label) Heparin-induced Thrombocytopenia The clinical relevance of these findings is unknown. Ask your doctor or pharmacist if you are unsure about it.
Uses of Biva
Bivalirudin is indicated for: Anticoagulant in Patients Undergoing PTCA/PCI or PCI with HITS/HITTS Unstable Angina/Non-ST-Elevation MI (Off-label) STEMI Undergoing Primary PCI (Off-label) Heparin-induced Thrombocytopenia Ask your doctor whether it is right for your condition.
How to use Biva
Biva is given as an injection by a healthcare professional. Do not inject it yourself unless a doctor has shown you how. Take Biva 250 mg/5 ml iv injection exactly as your doctor prescribes. Complete the course exactly as prescribed. If you miss a dose, ask your doctor or pharmacist what to do.
Side effects of Biva
Tell your doctor if any side effect bothers you or does not go away. Contact your doctor if you notice anything unusual after taking it.
Safety and precautions
Nursing Mothers : It is not known whether Bivalirudin is excreted in human milk. Coronary Artery Brachy therapy : An increased risk of thrombus formation, including fatal outcomes, has been associated with the use of Bivalirudin in gamma brachytherapy. No adequate and well-controlled studies in pregnant women. Ask your doctor first if any of these apply to you.
Frequently asked questions
What does Biva treat?
Bivalirudin is indicated for: Anticoagulant in Patients Undergoing PTCA/PCI or PCI with HITS/HITTS Unstable Angina/Non-ST-Elevation MI (Off-label) STEMI Undergoing Primary PCI (Off-label) Heparin-induced Thrombocytopenia Ask your doctor whether it is right for your condition.
How should I take Biva?
Biva is given as an injection by a healthcare professional. Do not inject it yourself unless a doctor has shown you how.
What are the side effects of Biva?
Tell your doctor if any side effect bothers you or does not go away. Contact your doctor if you notice anything unusual after taking it.
How much does Biva cost in Bangladesh?
The listed price is ৳ 10000.00.
- Strength
- 250 mg/5 ml
Price in Bangladesh
৳ 9800 ৳ 10000.00 2% off unit price
Price updated: 18 Nov 2026
Indications
Bivalirudin is indicated for:
- Anticoagulant in Patients Undergoing PTCA/PCI or PCI with HITS/HITTS
- Unstable Angina/Non-ST-Elevation MI (Off-label)
- STEMI Undergoing Primary PCI (Off-label)
- Heparin-induced Thrombocytopenia
Pharmacology
Bivalirudin directly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release. The binding of bivalirudin to thrombin is reversible as thrombin slowly cleaves the bivalirudin-Arg3-Pro4 bond, resulting in recovery of thrombin active site functions.
In in vitro studies, bivalirudin inhibited both soluble (free) and clot-bound thrombin, was not neutralized by products of the platelet release reaction, and prolonged the activated partialthromboplastin time (aPTT), thrombin time (TT), and prothrombin time (PT) of normal human plasma in a concentration-dependent manner. The clinical relevance of these findings is unknown.
Dosage & Administration
PCI/PTCA: IV Bolus dose of 0.75 mg/kg followed by an infusion of 1.75 mg/kg/h for duration of PCI procedure. Five minutes after bolus dose, obtain ACT and administer additional bolus of 0.3 mg/kg if indicated.
HIT/HITTS: IV Bolus dose of 0.75 mg/kg, followed by a continuous infusion at a rate of 1.75 mg/kg/h for the duration of the procedure.
Continuation of Therapy: IV Infusion may be continued for up to 4 h post-procedure as indicated. After 4 h, an additional IV infusion of 0.2 mg/kg/h for up to 20 h may be given if needed.
Concomitant Therapy: Bivalirudin is intended for concurrent use with aspirin (300 to 325 mg/day).
Interaction
Co-administration of Bivalirudin with heparin, warfarin, thrombolytics, or GPIs was associated with increased risks of major bleeding events.
Contraindications
Bivalirudin is contraindicated in patients with: Active major
bleeding & Hypersensitivity (e.g., anaphylaxis) to Bivalirudin or its components
Side Effects
- Bleeding, Body as a Whole: fever,infection, sepsis;
- Cardiovascular: hypotension, syncope, vascular anomaly,ventricular fibrillation;
- Nervous: cerebral ischemia, confusion, facialparalysis;
- Respiratory: lung edema;
- Urogenital: kidney failure, oliguria.
Pregnancy & Lactation
Pregnancy Category B. No adequate and well-controlled studies in pregnant women. As animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Bivalirudin is intended for use with aspirin . Because of possible adverse effects on the neonate and the potential for increased maternal bleeding, particularly during the third trimester, Bivalirudin and aspirin should be used together during pregnancy only if clearly needed.
Nursing Mothers: It is not known whether bivalirudin is excreted in human milk. As many drugs are excreted in human milk, caution should be exercised when Bivalirudin is administered to a nursing woman.
Precautions & Warnings
Bleeding Events: Although most bleeding associated with the use of Bivalirudin in PCI/PTCA occurs at the site of arterial puncture, hemorrhage can occur at any site. An unexplained fall in blood pressure or hematocrit should lead to serious consideration of a hemorrhagic event and cessation of Bivalirudin administration. Bivalirudin should be used with caution in patients with disease states associated with an increased risk of bleeding.
Coronary Artery Brachy therapy: An increased risk of thrombus formation, including fatal outcomes, has been associated with the use of Bivalirudin in gamma brachytherapy. If a decision is made to use Bivalirudin during brachytherapy procedures, maintain meticulous catheter technique, with frequent aspiration and flushing, paying special attention to minimizing conditions of stasis within the catheter or vessels.
Overdose Effects
Cases of overdose of up to 10 times the recommended bolus or continuous infusion dose of Bivalirudin have been reported in clinical trials and in postmarketing reports. A number of the reported overdoses were due to failure to adjust the infusion dose of bivalirudin in persons with renal dysfunction including persons on hemodialysis . Bleeding, as well as deaths due to hemorrhage, have been observed in some reports of overdose. In cases of suspected overdosage, discontinue Bivalirudin immediately and monitor the patient closely for signs of bleeding. There is no known antidote to Bivalirudin. Bivalirudin is hemodialyzable
Storage Conditions
Store at temperature not exceeding 30º C in a dry place. Do not freeze. Keep out of reach of children
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.